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Abstract
Major depressive disorder is one of the most common mental disorders in children and adolescents. However, whether to 
use pharmacological interventions in this population and which drug should be preferred are still matters of controversy. 
Consequently, we aimed to compare and rank antidepressants and placebo for major depressive disorder in young people.
We did a network meta-analysis to identify both direct and indirect evidence from relevant trials. We searched
PubMed, the Cochrane Library, Web of Science, Embase, CINAHL, PsycINFO, LiLACS, regulatory agencies’ websites,
and international registers for published and unpublished, double-blind randomised controlled trials up to
May 31, 2015, for the acute treatment of major depressive disorder in children and adolescents. We included trials of
amitriptyline, citalopram, clomipramine, desipramine, duloxetine, escitalopram, fl uoxetine, imipramine, mirtazapine,
nefazodone, nortriptyline, paroxetine, sertraline, and venlafaxine. Trials recruiting participants with treatmentresistant
depression, treatment duration of less than 4 weeks, or an overall sample size of less than ten patients were
excluded. We extracted the relevant information from the published reports with a predefi ned data extraction sheet,
and assessed the risk of bias with the Cochrane risk of bias tool. The primary outcomes were effi cacy (change in
depressive symptoms) and tolerability (discontinuations due to adverse events). We did pair-wise meta-analyses using
the random-eff ects model and then did a random-eff ects network meta-analysis within a Bayesian framework. We
assessed the quality of evidence contributing to each network estimate using the GRADE framework. This study is
registered with PROSPERO, number CRD42015016023.
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Comparative effi  cacy and tolerability of antidepressants for 
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Summary
Background Major depressive disorder is one of the most common mental disorders in children and adolescents. 
However, whether to use pharmacological interventions in this population and which drug should be preferred are 
still matters of controversy. Consequently, we aimed to compare and rank antidepressants and placebo for major 
depressive disorder in young people.
Methods We did a network meta-analysis to identify both direct and indirect evidence from relevant trials. We searched 
PubMed, the Cochrane Library, Web of Science, Embase, CINAHL, PsycINFO, LiLACS, regulatory agencies’ websites, 
and international registers for published and unpublished, double-blind randomised controlled trials up to 
May 31, 2015, for the acute treatment of major depressive disorder in children and adolescents. We included trials of 
amitriptyline, citalopram, clomipramine, desipramine, duloxetine, escitalopram, fl uoxetine, imipramine, mirtazapine, 
nefazodone, nortriptyline, paroxetine, sertraline, and venlafaxine. Trials recruiting participants with treatment-
resistant depression, treatment duration of less than 4 weeks, or an overall sample size of less than ten patients were 
excluded. We extracted the relevant information from the published reports with a predefi ned data extraction sheet, 
and assessed the risk of bias with the Cochrane risk of bias tool. The primary outcomes were effi  cacy (change in 
depressive symptoms) and tolerability (discontinuations due to adverse events). We did pair-wise meta-analyses using 
the random-eff ects model and then did a random-eff ects network meta-analysis within a Bayesian framework. We 
assessed the quality of evidence contributing to each network estimate using the GRADE framework. This study is 
registered with PROSPERO, number CRD42015016023.
Findings We deemed 34 trials eligible, including 5260 participants and 14 antidepressant treatments. The quality of 
evidence was rated as very low in most comparisons. For effi  cacy, only fl uoxetine was statistically signifi cantly more 
eff ective than placebo (standardised mean diff erence –0·51, 95% credible interval [CrI] –0·99 to –0·03). In terms of 
tolerability, fl uoxetine was also better than duloxetine (odds ratio [OR] 0·31, 95% CrI 0·13 to 0·95) and imipramine 
(0·23, 0·04 to 0·78). Patients given imipramine, venlafaxine, and duloxetine had more discontinuations due to 
adverse events than did those given placebo (5·49, 1·96 to 20·86; 3·19, 1·01 to 18·70; and 2·80, 1·20 to 9·42, 
respectively). In terms of heterogeneity, the global I² values were 33·21% for effi  cacy and 0% for tolerability.
Interpretation When considering the risk–benefi t profi le of antidepressants in the acute treatment of major depressive 
disorder, these drugs do not seem to off er a clear advantage for children and adolescents. Fluoxetine is probably the 
best option to consider when a pharmacological treatment is indicated.
Funding National Basic Research Program of China (973 Program).
Introduction
Major depressive disorder is common in young people 
with an estimated point prevalence of 2·8% in school-age 
children (aged 6–12 years) and 5·6% in adolescents 
(aged 13–18 years).1 Compared with adults, children and 
adolescents with major depressive disorder are still 
underdiagnosed and undertreated,2 possibly because they 
tend to present with rather undiff erentiated depressive 
symptoms—eg, irritability, aggressive behaviours, and 
school refusal.3 Consequences of depressive episodes in 
these patients include serious impairments in social 
functioning, and suicidal ideation and attempts.4 Even 
though psychological treatments are still considered the 
fi rst-line treatment in many clinical guidelines,4,5 
antidepressants are widely used in the treatment of 
depression in children and adolescents and the rate of 
prescription has increased over time.6 However, in 2004, 
the US Food and Drug Administration (FDA) cautioned 
practitioners on the use of antidepressants in children 
and adolescents because of increased suicide risk.7 
Consequently, the question of whether to use 
antidepressant drugs for the treatment of major 
depressive disorder in young people and, if so, which 
antidepressant would be preferred, remains controversial.3
Previous pairwise meta-analyses were done to evaluate 
the effi  cacy of all types of antidepressants8,9 and to 
identify factors associated with treatment effi  cacy.10 
However, these studies were inconclusive because they 
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were not able to generate clear hierarchies among 
available treatments, because many antidepressants have 
not been directly compared. Therefore, we did a network 
meta-analysis to comprehensively compare and rank 
antidepressants for the acute treatment of major 
depressive disorder in children and adolescents.
Methods
Search strategy and selection criteria
For this network meta-analysis, we searched PubMed, 
the Cochrane Central Register of Controlled Trials, Web 
of Science, Embase, CINAHL, PsycINFO, and LiLACS 
for double-blind randomised controlled trials (RCTs) 
published from the date of database inception to 
May 31, 2015, comparing any antidepressant with 
placebo or another active antidepressant as oral 
monotherapy in the acute treatment of children and 
adolescents (mean age 9–18 years at enrolment in the 
primary study), with a primary diagnosis of major 
depressive disorder according to standardised 
diagnostic criteria. We also screened international trial 
registers and relevant reports on the FDA website, and 
searched key scientifi c journals in the fi eld for 
published and unpublished studies (see appendix 
p 4 for more details).11 We put no restrictions on 
language. For data about suicidality, we referred to the 
original papers, the Columbia University re-analysis of 
the FDA report,12 and additionally searched the 
Medicines and Healthcare Products Regulatory Agency 
database and pharma ceutical company websites for 
unpublished data. Study authors and drug 
manufacturers were contacted to supplement 
incomplete reports of the original papers or provide 
data for unpublished studies.
We included the following antidepressant 
interventions, but only if administered within the 
therapeutic dose range: amitriptyline, citalopram, 
clomipramine, desipramine, duloxetine, escitalopram, 
fl uoxetine, imipramine, mirtazapine, nefazodone, 
nortriptyline, paroxetine, sertraline, and venlafaxine. 
Trials involving patients with comorbid, non-aff ective 
psychiatric disorders were included; however, 
RCTs recruiting participants with treatment-resistant 
depression, with treatment duration of less than 4 weeks, 
or with an overall sample size of fewer than ten patients 
were excluded.
Data extraction and quality assessment
Four investigators (AC, SEH, BQ, and YL) selected 
studies independently, and four investigators (YZ, BQ, 
YL, and LY) independently reviewed the main reports 
and supplementary materials, extracted the relevant 
information from the included trials with a predefi ned 
data extraction sheet, and assessed the risk of bias with 
the Cochrane risk of bias tool.13 Any discrepancies were 
resolved by consensus and arbitration by a panel of other 
investigators within the review team (AC, SEH, DC, SL, 
XZ, and PX).
See Online for appendix
Research in context
Evidence before this study
Even though psychological treatments are still considered the 
fi rst-line treatment, antidepressants are widely used in the 
treatment of depression in children and adolescents. We searched 
PubMed for previously published meta-analyses on 
antidepressants in children and adolescents, with the search 
terms “depressive disorder”, “child”, and “adolescent”. Previous 
pairwise meta-analyses have been inconclusive because they 
could not generate clear hierarchies among available treatments, 
because many antidepressants have not been directly compared.
Added value of this study
Our study provides the fi rst comprehensive systematic review 
and network meta-analysis of all available double-blind 
randomised trials, comparing any antidepressant with placebo 
or another active antidepressant as oral monotherapy in the 
acute treatment of major depressive disorder in children and 
adolescents (mean age 9–18 years). Our fi ndings emphasise 
that only fl uoxetine is signifi cantly more effi  cacious than 
placebo and some other active drugs at reducing depressive 
symptoms or the number of discontinuations due to adverse 
events over 8 weeks. Furthermore, we found robust evidence to 
suggest a signifi cantly increased risk for suicidality (suicidal 
behaviour or ideation) for young people given venlafaxine.
Implications of all the available evidence
Our study has several implications for clinical practice. First, our 
fi ndings suggest that fl uoxetine should be considered the best 
available choice when a pharmacological treatment is indicated 
for moderate-to-severe depression in people younger than 
18 years who do not have access to psychotherapy or have not 
responded to non-pharmacological interventions. Other 
antidepressants do not seem to be suitable as routine 
treatment options. Second, venlafaxine was found to be 
associated with an increased risk of suicidality in the young 
population. Because of the absence of reliable data on 
suicidality for many antidepressants, we could not 
comprehensively assess the risk of suicidality for all drugs. 
However, from a clinical perspective, children and adolescents 
taking antidepressant drugs should be closely monitored 
regardless of the treatment chosen, particularly at the 
beginning of treatment. Finally, we found that the methods 
used in individual studies were poor. Together with selective 
reporting, these are important limitations to be considered 
when interpreting the results from studies in such a population. 
Without access to individual patient-level data, we cannot be 
completely confi dent about the accuracy of information 
contained in published studies or clinical study reports. 
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Outcomes
We considered the mean overall change in depressive 
symptoms from baseline to endpoint and the proportion 
of patients who discontinued treatment due to any 
adverse events for our primary analyses. To measure 
improvement in depressive symptoms, the Children’s 
Depression Rating Scale Revised (CDRS-R; a clinician-
rated scale adapted for children and adolescents from the 
Hamilton Depression Rating Scale [HAMD], which is a 
tool validated and commonly used in adults [both 
CDRS-R and HAMD have good reliability and validity; 
appendix p 2]), and the Beck Depression Inventory and 
the Children’s Depression Inventory (the two most 
commonly used among depression symptom severity 
self-rated scales) were used by the study investigators and 
we extracted the score data. When depression symptoms 
had been measured with more than one standardised 
rating scale, we used a predefi ned hierarchy, based on 
psychometric properties, frequency of use in children 
and adolescents, and consistency of use across included 
trials (appendix p 6). Secondary outcomes included 
response rate (estimated as the proportion of patients 
who achieved a reduction of 50% or more in depression 
rating score, or who scored much or very much improved 
on the Clinical Global Impression scale), all-cause 
discontinuation, and suicidal behaviour or ideation. We 
defi ned acute treatment as 8 weeks of treatment for both 
effi  cacy and tolerability analyses.14 If data at 8 weeks were 
not available, we used data ranging between 4 and 
16 weeks (we gave preference to the timepoint used in 
the original study as the study endpoint).
Statistical analysis
Details of the applied statistical approaches are provided 
in the appendix (p 2, 8). First, we did pairwise meta-
analyses with the random-eff ects model with STATA 
(version 13.0). The standardised mean diff erence (SMD) 
was calculated as the eff ect size for continuous outcomes 
and the odds ratio (OR) was calculated for dichotomous 
outcomes, both with 95% CI. We assessed statistical 
heterogeneity in each pairwise comparison with the I² 
statistic and p value.13 We used the funnel plot and 
Egger’s test to detect publication bias, if at least ten 
studies were available.13
Second, we did a random-eff ects network meta-
analysis within a Bayesian framework with WinBUGS 
(version 1.4.3) and further analysis with STATA 
(version 13.0) and R (version 3.2.2). We summarised the 
results of network meta-analysis with eff ect sizes (SMD 
or OR) and their credible intervals (CrI).15 See appendix 
(p 8) for details about the WinBUGS codes used. The 
pooled estimates were obtained using the Markov 
Chains Monte Carlo method. Two Markov chains were 
run simultaneously with diff erent arbitrarily chosen 
initial values. To ensure convergence, trace plots and the 
Brooks-Gelman-Rubin statistic were assessed.16 A 
common heterogeneity parameter was assumed for all 
comparisons and we assessed the global heterogeneity 
using the I² statistic with the GeMTC R package 
(version 3.2.2).17 Inconsistency between direct and 
indirect sources of evidence was statistically assessed 
globally (by comparison of the fi t and parsimony of 
consistency and inconsistency models) and locally (by 
calculation of the diff erence between direct and indirect 
estimates in all closed loops in the network).18 The node 
splitting method was used to calculate the inconsistency 
of the model, which separated evidence on a particular 
comparison into direct and indirect evidence.19 We 
estimated the ranking probabilities for all treatments of 
being at each possible rank for each intervention. The 
treatment hierarchy was summarised and reported as 
surface under the cumulative ranking curve (SUCRA).20 
We also plotted a comparison-adjusted funnel plot for 
the network meta-analysis, to detect the presence of any 
dominant publication bias in network meta-analysis.20 
Additionally, we assessed the quality of evidence 
contributing to each network estimate using the GRADE 
framework, which characterises the quality of a body 
of evidence on the basis of the study limitations, 
imprecision, inconsistency, indirectness, and publication 
bias for the primary outcomes.21
To determine whether the results were aff ected by study 
characteristics, we did subgroup network meta-analyses 
in WinBUGS for primary outcomes according to the 
following variables: sex ratio, age group, treatment 
duration, severity of symptoms (see appendix p 12 for 
details), comorbid psychiatric disorder, quality of study, 
sample size, and sponsorship. Additionally, we did 
sensitivity network meta-analyses for primary outcomes 
by omitting unpublished trials, and trials in which 
response was imputed using remission rate.
This study is registered with PROSPERO, number 
CRD42015016023. The full dataset is available online.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, writing 
of the report, or in the decision to submit for publication. 
AC, XZ, CDG, and PX had full access to all the data, and 
AC and PX were responsible for the decision to submit 
for publication.
Results
Overall, 5794 citations were identifi ed by the search and 
165 potentially eligible articles were retrieved in full 
text (fi gure 1). We excluded 138 reports, but included 
four additional studies from trial registers and pharma-
ceutical company websites, resulting in 31 publications 
describing 34 parallel RCTs (5260 patients) published 
between 1986 and 2014 and comparing 14 antidepressants 
or placebo (fi gure 1 and table 1). Seven of the included 
trials were unpublished and two were not in English (full 
references for all trials are given in the appendix p 14). 
The mean study sample size was 159 participants, 
For the full dataset see 
http://ora.ox.ac.uk/objects/
uuid:a4d1186b-6be4-486a-
b9ce-ce431ccd545b
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ranging between 23 and 463 patients. Overall, 
3106 participants were randomly assigned to an active 
drug and 2154 to placebo. Only 25 randomised controlled 
trials reported full clinical and demographic 
characteristics (table 1); about half of the sample 
population were female (2348 [53%] of 4432) and the 
mean age was 13·6 years (SD 2·87). The median duration 
of the acute treatment was 8 weeks (range 5–12) and 82% 
of trials (28 of 34) enrolled children and adolescents with 
moderate-to-severe depressive symptoms. 17 (50%) trials 
recruited patients from North America, fi ve (15%) from 
across continents, and four (12%) from Europe. Of the 
remaining trials, four (12%) recruited participants from 
other countries and four (12%) trials did not specify. 
22 (65%) trials were funded by pharmaceutical 
companies. In terms of study quality, ten (29%) trials 
were rated as high risk of bias, 20 (59%) trials as 
moderate, and four (12%) as low (appendix p 18).
Figure 2 shows the network of eligible comparisons for 
effi  cacy. For graphical representation of the other 
networks see appendix (p 22). All antidepressant drugs, 
except for clomipramine, had at least one placebo-
controlled trial and fi ve drugs were directly compared 
with at least one other active drug. Detailed results of 
pairwise meta-analyses are given in the appendix (p 25). 
Fluoxetine, sertraline, and escitalopram were statistically 
more effi  cacious than placebo in both continuous and 
dichotomous outcomes; fl uoxetine was superior to 
nortriptyline, wherease paroxetine showed a signifi cant 
benefi t in terms of mean overall change in symptoms 
(not signifi cant in terms of response rate) compared with 
clomipramine. For tolerability (as assessed by OR of 
discontinuation due to adverse eff ects), duloxetine, 
imipramine, sertraline, and venlafaxine were not as well 
tolerated as placebo; and paroxetine was not as well 
tolerated as imipramine (appendix p 29).
The results of the network meta-analyses for the primary 
outcomes is presented as a league table in fi gure 3. In 
terms of effi  cacy, only fl uoxetine was better than placebo 
(SMD –0·51, 95% CrI –0·99 to –0·03). Nortriptyline was 
signifi cantly less eff ective than seven other antidepressants 
and placebo (SMDs ranging between –1·65 and –1·14). In 
terms of tolerability, fl uoxetine was signifi cantly better 
tolerated than duloxetine (OR 0·31, 95% CrI 0·13 to 0·95) 
and imipramine (0·23, 0·04 to 0·78), and citalopram 
and paroxetine were signifi cantly better tolerated than 
imipramine alone (0·27, 0·04 to 0·96 and 0·22, 
0·08 to 0·87, respectively). Imipramine was signifi cantly 
less well tolerated than placebo (5·49, 1·96 to 20·86) as 
was venlafaxine (3·19, 1·01 to 18·70) and duloxetine (2·80, 
1·20 to 9·42). Results for secondary outcomes of response 
rate and all-cause discontinuation were not materially 
diff erent from, and lent support to, the fi ndings for 
primary outcomes (appendix p 34). The only exception 
was nefazodone, which was more effi  cacious and better 
tolerated in the secondary analyses than in the primary 
analyses, but this evidence was based on only one 
Figure 1: Study selection
RCT=randomised controlled trial. 
5794 records identified by database search 
1790 duplicates excluded
3839 titles and abstracts excluded
 1977 not original investigations
 896 not RCTs
 681 did not assess major depressive
  disorder
 131 not double blind
 95 trials in adults
 59 other publication from the same
  trial
3 publications from trial registers 
1 data from inquiries to pharmaceutical 
 companies  
4004 titles and abstracts reviewed
138 full-text articles excluded  
 35 duplicates 
 21 non-randomised design 
 7 meeting abstracts (unable to extract 
  any data) 
 9 reviews or pooled analyses 
 7 included non-depressed patients 
 3 included treatment-resistant 
  depression 
 20 included adults, data for children or 
  adolescents could not be extracted 
  separately 
 22 no relevant intervention 
 9 did not report outcomes that meet 
  inclusion criteria 
 2 sample size fewer than ten patients  
 1 follow-up time less than 4 weeks 
 1 no standardised diagnosis of major 
  depressive disorder
 1 no double-blind design 
31 publications (corresponding to 34 RCTS
  and 40 pairs of investigations) included in the
  network meta-analysis
 1 comparing amitriptyline with placebo 
 2 comparing citalopram with placebo 
 1 comparing clomipramine with another 
  drug 
 2 comparing desipramine with placebo 
 2 comparing duloxetine with another 
  drug or placebo 
 2 comparing escitalopram with placebo 
 10 comparing fluoxetine with other drugs 
  or placebo 
 3 comparing imipramine with another 
  drug or placebo 
 2 comparing mirtazapine with placebo 
 2 comparing nefazodone with placebo 
 3 comparing nortriptyline with another 
  drug or placebo 
 5 comparing paroxetine with other drugs 
  or placebo 
 2 comparing sertraline with placebo 
 3 comparing venlafaxine with another 
  drug or placebo 
26 detailed screening excluded 
 14 duplicates 
 2 non-randomised design 
 6 no available data
 4 ongoing studies 
29  detailed screening reviewed
2480 titles excluded
2509 records identified from trial registers  165 full-text articles reviewed
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Diagnostic 
criteria
Treatments, n (dose range) Treatment 
duration 
(weeks)
Age range 
(mean)
Proportion 
of girls or 
women (%)
Recruiting area Setting Funder
Organon (2002a) DSM-IV Mirtazapine, 82 (15–45 mg/day)
Placebo, 44
8 7–18 (12·3) 51% Europe Outpatients Organon
Organon (2002b) DSM-IV Mirtazapine, 88 (15–45 mg/day)
Placebo, 45
8 7–18 (12·0) 53% Europe Outpatients Organon
 Almeida-Montes et 
al (2005)
 DSM-IV-TR Fluoxetine, 12 (20 mg/day)
Placebo, 11
6 8–14 (11·4) 35% Mexico Outpatients None*
Atkinson et al (2014) DSM-IV-TR Duloxetine, 117 (60–120 mg/day)
Fluoxetine, 117 (20–40 mg/day)
Placebo, 103
10 7–17 (13·2) 52% USA, Finland, France, 
Germany, Russia, 
Slovakia, Estonia, 
Ukraine, South Africa
Outpatients Eli Lilly
Attari et al (2006) DSM-IV Fluoxetine, 20 (0·5–2 mg/day per kg) 
Nortriptyline, 20 (1–2 mg/day per kg)
8 7–16 (12·9) 50% Iran Outpatients Not stated
Eli Lilly (1986) DSM III Fluoxetine, 21 (20–60 mg/day)
Placebo, 19
6 12–17 (15·6) 55% Canada Inpatients and 
outpatients
Eli Lilly
Berard et al (2006) DSM-IV Paroxetine, 187 (20–40 mg/day)
Placebo, 99
12 13–18 (15·6) 67% Belgium, Italy, Mexico, 
UK, Spain, Netherlands, 
Canada, South Africa, 
United Arab Emirates, 
Argentina
Outpatients GlaxoSmithKline
Braconnier et al 
(2003)
DSM-IV Clomipramine, 58 (75–150 mg/day) 
Paroxetine, 63 (20–40 mg/day)
8 12–20 (16·1) 60% France ·· GlaxoSmithKline
Bristol-Myers Squibb 
(2002)
DSM-IV Nefazodone, 95 (100–300 mg/day) 
Nefazodone, 95 (200–600 mg/day)
Placebo, 94
8 7–17 (··) ·· ·· ·· Bristol-Myers 
Squibb
Emslie et al (1997) DSM III-R Fluoxetine, 48 (20 mg/day)
Placebo, 48
8 7–17 (12·4) 46% USA Outpatients None
Emslie et al (2002a) DSM-IV Fluoxetine, 109 (10–20 mg/day) 
Placebo, 110
9 8–18 (12·7) 49% USA Outpatients Eli Lilly
Emslie et al (2002b) DSM-IV Nefazodone, 99 (100–400 mg/day)
Placebo, 96
8 12–17 (··) 59% ·· ·· Bristol-Myers 
Squibb
Emslie et al (2006) DSM-IV Paroxetine, 104 (10–50 mg/day) 
Placebo, 102
8 7–17 (12·0) 47% USA and Canada ·· GlaxoSmithKline
Emslie et al (2007)† DSM-IV Venlafaxine, 184 (37·5–225 mg/day) 
Placebo, 183
8 7–17 (12·3) 46% USA Outpatients Wyeth Research
Emslie et al (2009) DSM-IV Escitalopram, 158 (10–20 mg/day) 
Placebo, 158
8 12–17 (14·6) 59% USA Outpatients Forest 
Laboratories
Emslie et al (2014) DSM-IV-TR Duloxetine, 108 (60 mg/day) 
Duloxetine, 116 (30 mg/day) 
Fluoxetine, 117 (20 mg/day) 
Placebo, 122
10 7–17 (13·0) 51% USA, Argentina, 
Canada, Mexico
Outpatients Eli Lilly
Findling et al (2009) DSM-IV Fluoxetine, 18 (10–20 mg/day) 
Placebo, 16
8 12–17 (16·5) 15% USA Outpatients Eli Lilly
Geller et al (1990) DSM-III Nortriptyline, 12 (45–140 mg/day) 
Placebo, 19
8 12–17 (14·3) 45% USA Outpatients None
Geller et al (1992) DSM III Nortriptyline, 30 (10–140 mg/day) 
Placebo, 30
8 6–12 (9·7) 30% ·· Outpatients None
Hongfen et al (2009) CCMD-3 Fluoxetine, 30 (20 mg/day) 
Venlafaxine, 30 (150 mg/day)
8 12–18 (15·8) 47% China Inpatients and 
outpatients
Not stated
Hughes et al (1990) DSM-III Imipramine, 13 (..) 
Placebo, 14
6 6–12 (··) ·· ·· Inpatients None
Keller et al (2001) DSM-IV Imipramine, 95 (50–300 mg/day) 
Paroxetine, 93 (20–40 mg/day) 
Placebo, 87
8 12–18 (14·9) 62% USA, Canada ·· GlaxoSmithKline
Klein et al (1998) DSM-III-R Desipramine, 23 (50–300 mg/day) 
Placebo, 22
6 13–18 (15·7) 67% USA Outpatients None
Kutcher et al (1994) DSM-III-R Desipramine, 30 (200 mg/day) 
Placebo, 30
6 15–19 (17·8) 70% Canada Outpatients None
Kye et al (1996) K-SADS 
and RDC
Amitriptyline, 18 (5 mg/day per kg)
Placebo, 13
8 12–17 (14·8) 29% USA Outpatients None
(Table 1 continues on next page)
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unpublished trial of poor quality, which is a major 
limitation for the reliability of fi ndings (appendix p 35). 
Figure 4 shows the network meta-analyses results of the 
suicide-related outcome (actual number of patients with 
suicidal behaviour or ideation are in table 2). Venlafaxine 
was associated with a signifi cantly increased risk of 
suicidal behaviour or ideation compared with placebo 
(OR 0·13, 95% CrI 0·00–0·55) and fi ve other 
antidepressants (escitalopram, imipramine, duloxetine, 
fl uoxetine, and paroxetine).
The common heterogeneity SD was 0·68 (95% CrI 
0·47–0·94) for effi  cacy, 0·42 (0·02–0·94) for tolerability, 
0·22 (0·01–0·50) for response rate, 0·32 (0·03–0·67) for 
all-cause discontinuation, and 0·30 (0·01–0·84) for 
suicide-related outcome. The global I² values were 
33·21% for effi  cacy and 0% for tolerability. The test of 
global inconsistency showed a signifi cant diff erence 
between the consistency and inconsistency models for 
effi  cacy (p<0·0001), but not for tolerability (p=0·8432; 
appendix p 36). Tests of local inconsistency showed that 
the percentages for inconsistent loops were to be expected 
based on the empirical data (two of four comparison 
loops for the effi  cacy outcome and zero of two for 
tolerability outcome; for details of the assessments of 
consistency see appendix p 38). The test of inconsistency 
from the node-splitting model showed signifi cant 
diff erences between some comparisons in primary 
effi  cacy, but not for tolerability (appendix p 41). The 
comparison-adjusted funnel plots of the network 
meta-analysis for primary outcomes were not suggestive 
of any publication bias (appendix p 44).
The ranking of treatments based on cumulative 
probability plots and SUCRAs is presented in the 
appendix (p 48). In terms of effi  cacy, the most eff ective 
Diagnostic 
criteria
Treatments, n (dose range) Treatment 
duration 
(weeks)
Age range 
(mean)
Proportion 
of girls or 
women (%)
Recruiting area Setting Funder
(Continued from previous page)
March et al (2004) DSM-IV Fluoxetine , 109 (10–40 mg/day)
Placebo, 112
12 12–17 (14·6) 54% USA Outpatients None
GlaxoSmithKline 
(2009)
DSM-IV-TR Paroxetine, 29 (10–40 mg/day) 
Placebo, 27
8 7–17 (14·6) 61% Japan ·· GlaxoSmithKline
Puig-Antich et al 
(1987)
K-SADS 
and RDC
Imipramine, 20 (3·25–5 mg/day per kg) 
Placebo, 22
5 6–12 (9·1) 40% USA Inpatients 
and 
outpatients
None
von Knorring et al 
(2006)
DSM-IV Citalopram, 124 (10–40 mg/day) 
Placebo , 120
12 13–18 (16·0) ·· Europe Inpatients and 
outpatients
Lundbeck
Wagner et al (2003a) DSM-IV Sertraline, 97 (50–200 mg/day)
Placebo, 91
10 6–17 (··) 51% USA, Costa Rica, India, 
Canada, Mexico
Outpatients Pfi zer
Wagner et al (2003b) DSM-IV Sertraline, 92 (50–200 mg/day) 
Placebo, 96
10 6–17 (··) 52% USA, Costa Rica, India, 
Canada, Mexico
Outpatients Pfi zer
Wagner et al (2004) DSM-IV Citalopram, 93 (20–40 mg/day)
Placebo, 85
8 7–17 (12·1) 53% USA ·· Forest 
Laboratories
Wagner et al (2006) DSM-IV Escitalopram, 132 (10–20 mg/day) 
Placebo, 136
8 6–17 (12·3) 52% USA Outpatients Forest 
Laboratories
Full references for all trials are given in the appendix (p 14). DSM=Diagnostic and Statistical Manual of Mental Disorders. DSM-IV-TR=Diagnostic and Statistical Manual of Mental Disorders fourth edition, text 
revision. CCMD-3=Chinese Classifi cation of Mental Disorders third version. K-SADS=Kiddie-Schedule for Aff ective Disorders and Schizophrenia for School-Age Children. RDC=Research Diagnostic Criteria. 
*The authors stated that fl uoxetine and placebo were donated by Eli Lilly, but this company was not involved in the design, planning, implementation, collection, analysis, and presentation of the results of this 
study. †This publication reports the combined data from two similarly designed controlled studies comparing venlafaxine with placebo.
Table 1: Randomised controlled trials included in the systematic review and network meta-analysis
Figure 2: Network of eligible comparisons for effi  cacy
The width of the lines is proportional to the number of trials comparing every pair of treatments, and the size of 
every circle is proportional to the number of randomly assigned participants (sample size).
Amitriptyline
Citalopram
Clomipramine
Desipramine
Duloxetine
Escitalopram
Fluoxetine
Imipramine
Mirtazapine
Nefazodone
Nortriptyline
Paroxetine
Placebo
Sertraline
Venlafaxine
Articles
www.thelancet.com   Vol 387www.thelancet.com   Published online June 8, 2016   http://dx.doi.org/10.1016/S0140-6736(16)30385-3 7
treatment was fl uoxetine (76·6%) and the least eff ective 
was nortriptyline (3·7%). In terms of tolerability, 
fl uoxetine was the best drug (75·7%) and imipramine the 
worst (13·1%). According to GRADE, the quality of 
evidence for primary outcomes was rated as very low for 
most comparisons (appendix p 77–86). Quality of 
evidence was very low for overall ranking of treatment in 
terms of effi  cacy and low for tolerability (appendix 
p 82, 86). We also studied the eff ect of several potential 
moderator variables for the primary outcomes in 
subgroup analyses, the fi ndings of which were not 
materially diff erent from those of the primary analysis 
for most of these comparisons (appendix p 87). 
Preplanned sensitivity analyses did not aff ect the main 
results (appendix p 92).
Discussion
This network meta-analysis represents the most 
comprehensive synthesis of data for currently available 
pharmacological treatments for children and adolescents 
with acute major depressive disorder. We found that only 
fl uoxetine was signifi cantly more eff ective than placebo, 
and the corresponding SMD of 0·51 is considered to be a 
medium eff ect size.22 However, the large credible interval 
and its upper limit close to the point of no diff erence 
raise the question of whether this estimate is robust 
enough to inform clinical practice. By comparison with 
placebo, fl uoxetine was signifi cantly more eff ective in 
Figure 3: Network meta-analysis of effi  cacy and tolerability
Drugs are reported in order of effi  cacy ranking according to SUCRAs. Comparisons should be read from left to right. The effi  cacy and tolerability estimate is located at the intersection of the 
column-defi ning treatment and the row-defi ning treatment. For effi  cacy (mean overall change in symptoms), an SMD below 0 favours the column-defi ning treatment. For tolerability (discontinuation 
due to adverse events), an OR below 1 favours the row-defi ning treatment. To obtain SMDs for comparisons in the opposing direction, negative values should be converted into positive values and vice 
versa. To obtain ORs for comparisons in the opposing direction, reciprocals should be taken. Signifi cant results are in bold and underlined. AMI=amitriptyline. CIT=citalopram. CLO=clomipramine. 
CrI=credibility interval. DES=desipramine. DUL=duloxetine. ESC=escitalopram. FLU=fl uoxetine. IMP=imipramine. MIR=mirtazapine. NEF=nefazodone. NOR=nortriptyline. OR=odds ratio. 
PAR=paroxetine. PBO=placebo. SER=sertraline. SMD=standardised mean diff erence. SUCRA=surface under the cumulative ranking curve. VEN=venlafaxine.
FLU
DES
DUL
VEN
MIR
SER
CIT
ESC
PAR
NEF
IMP
AMI
PBO
CLO
NOR
Treatment Efficacy (mean overall change in symptoms, SMD [95% Crl]) Tolerability (discontinuation due to adverse events, OR [95% Crl])
0·18
(0·04 to 1·75)
0·31
(0·13 to 0·95)
0·39
(0·05 to 1·47)
0·91
(0·09 to 3·49)
0·43
(0·06 to 1·58)
0·69
(0·24 to 3·50)
0·30
(0·07 to 3·06)
0·78
(0·21 to 2·18)
0·96
(0·05 to 4·56)
0·23
(0·04 to 0·78)
0·11
(0·03 to 77·0)
1·03
(0·50 to 2·70)
0·43
(0·11 to 3·98) ¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
¨
2·05
(0·18 to 8·72)
1·79
(0·11 to 8·70)
4·23
(0·19 to 20·49)
1·96
(0·12 to 9·40)
1·90
(0·47 to 22·04)
3·55
(0·16 to 17·62)
3·61
(0·39 to 14·96)
4·38
(0·11 to 24·29)
1·09
(0·09 to 4·95)
0·32
(0·09 to 377·5)
2·85
(0·83 to 21·80)
1·17
(0·25 to 22·42)
–0·10
(–1·49 to1·28)
1·17
(0·13 to 4·68)
2·73
(0·23 to 11·00)
1·27
(0·14 to 5·05)
1·89
(0·61 to 11·49)
2·27
(0·19 to 9·64)
2·32
(0·53 to 7·26)
2·88
(0·12 to 14·26)
0·68
(0·11 to 2·54)
0·33
(0·09 to 224·8)
2·80
(1·20 to 9·42)
1·17
(0·30 to 12·58)
–0·19
(–1·54 to 1·17)
–0·09
(–1·28 to 1·10)
1·17
(0·23 to 18·93)
0·61
(0·14 to 8·69)
2·13
(0·56 to 20·32)
0·92
(0·19 to 16·01)
1·69
(0·47 to 13·33)
0·71
(0·13 to 22·98)
0·40
(0·10 to 4·39)
0·37
(0·10 to 343·2)
3·19
(1·01 to 18·70)
1·30
(0·29 to 21·16)
–0·21
(–1·68 to 1·26)
–0·11
(–1·46 to 1·23)
–0·02
(–1·33 to 1·28)
0·93
(0·06 to 4·52)
0·91
(0·23 to 10·97)
0·40
(0·08 to 8·51)
1·71
(0·20 to 7·49)
2·12
(0·05 to 12·37)
0·17
(0·04 to 2·27)
0·18
(0·05 to 151·0)
1·36
(0·41 to 10·99)
0·56
(0·12 to 10·82)
–0·22
(–1·68 to 1·24)
–0·12
(–1·46 to 1·21)
–0·03
(–1·34 to 1·27)
–0·01
(–1·43 to 1·40)
1·98
(0·52 to 18·57)
0·85
(0·17 to 15·06)
1·56
(0·44 to 12·09)
0·64
(0·11 to 21·50)
0·37
(0·09 to 4·05)
0·35
(0·09 to 304·7)
2·94
(0·94 to 17·19)
1·20
(0·27 to 18·95)
–0·27
(–1·72 to 1·20)
–0·17
(–1·50 to 1·17)
–0·08
(–1·38 to 1·22)
–0·06
(–1·47 to 1·35)
–0·05
(–1·45 to 1·35)
0·91
(0·07 to 3·89)
0·93
(0·20 to 2·77)
1·17
(0·05 to 5·60)
0·27
(0·04 to 0·96)
0·13
(0·03 to 91·24)
1·13
(0·45 to 3·66)
1·18
(0·11 to 4·76)
–0·28
(–1·73 to 1·17)
–0·18
(–1·51 to 1·15)
–0·09 
(–1·39 to 1·20)
–0·07
(–1·48 to 1·34)
–0·06
(–1·45 to 1·34)
–0·01
(–1·41 to 1·40)
2·19
(0·22 to 9·23)
2·67
(0·06 to 14·62)
0·63
(0·05 to 2·87)
0·16
(0·05 to 196·9)
1·64
(0·46 to 13·49)
0·68
(0·14 to 13·64)
–0·29
(–1·56 to 0·99)
–0·19
(–1·32 to 0·94)
–0·10
(–1·19 to 0·99)
–0·07
(–1·30 to 1·15)
–0·07
(–1·28 to 1·16)
–0·02
(–1·23 to 1·19)
–0·01
(–1·21 to 1·20)
0·35
(0·07 to 6·80)
0·22
(0·08 to 0·87)
0·19
(0·05 to 115·6)
1·59
(0·77 to 3·95)
0·79
(0·26 to 3·77)
–0·30
(–1·76 to 1·15)
–0·20
(–1·54 to 1·13)
–0·11
(–1·42 to 1·18)
–0·09
(–1·50 to 1·32)
–0·08
(–1·48 to 1·32)
–0·03
(–1·44 to 1·37)
–0·02
(–1·42 to 1·37)
–0·01
(–1·23 to 1·19)
0·16
(0·03 to 4·50)
0·11
(0·04 to 241·2)
1·29
(0·30 to 21·89)
0·52
(0·10 to 20·79)
–0·44
(–1·88 to 1·01)
–0·33
(–1·65 to 0·98)
–0·25
(–1·53 to 1·03)
–0·22
(–1·61 to 1·17)
–0·22
(–1·60 to 1·17)
–0·17
(–1·55 to 1·22)
–0·16
(–1·54 to 1·22)
–0·15
(–1·21 to 0·91)
–0·13
(–1·52 to 1·26)
0·67
(0·17 to 471·9)
5·49
(1·96 to 20·86)
2·47
(0·62 to 21·47)
–0·53
(–2·39 to 1·33)
–0·43
(–2·20 to 1·34)
–0·34
(–2·09 to 1·40)
–0·32
(–2·14 to 1·52)
–0·31
(–2·13 to 1·52)
–0·26
(–2·10 to 1·57)
–0·25
(–2·08 to 1·57)
–0·24
(–1·92 to 1·43)
–0·23
(–2·05 to 1·59)
–0·10
(–1·92 to 1·71)
0·10
(0·02 to 32·16)
6·38
(0·01 to 24·56)
–0·45
(–1·52 to 0·62)
–0·35
(–1·24 to 0·54)
–0·26
(–1·10 to 0·58)
–0·24
(–1·25 to 0·77)
–0·23
(–1·21 to 0·77)
–0·18
(–1·18 to 0·82)
–0·17
(–1·15 to 0·81)
–0·16
(–0·86 to 0·54)
–0·15
(–1·14 to 0·85)
–0·01
(–0·98 to 0·95)
0·08
(–1·45 to 1·61)
0·79
(0·12 to 2·75)
–0·77
(–2·67 to 1·13)
–0·67
(–2·49 to 1·14)
–0·58
(–2·38 to 1·20)
–0·56 
(–2·43 to 1·32)
–0·55
(–2·42 to 1·31)
–0·50
(–2·36 to 1·36)
–0·49
(–2·35 to 1·36)
–0·48
(–1·90 to 0·93)
–0·47
(–2·33 to 1·39)
–0·34
(–2·10 to 1·43)
–0·24
(–2·43 to 1·95)
–0·32
(–1·90 to 1·25)
–1·59
(–2·98 to –0·21)
–0·06
(–1·23 to 1·11)
–0·16
(–1·05 to 0·72)
–0·25
(–1·13 to 0·64)
–0·27
(–1·39 to 0·84)
–0·28
(–1·38 to 0·82)
–0·33
(–1·43 to 0·78)
–0·34
(–1·44 to 0·75)
–0·35 
(–1·19 to 0·50)
–0·36
(–1·46 to 0·74)
–0·49
(–1·57 to 0·58)
–0·59
(–2·21 to 1·01)
–0·51
(–0·99 to –0·03)
–0·83
(–2·48 to 0·81)
–1·65 
(–2·57 to –0·72)
–1·49
(–2·71 to –0·27)
–1·40
(–2·60 to –0·20)
–1·38
(–2·71 to –0·04)
–1·37
(–2·70 to –0·05)
–1·32
(–2·65 to 0·01)
–1·31
(–2·63 to 0·01)
–1·30
(–2·43 to –0·18)
–1·29
(–2·61 to 0·04)
–1·15
(–2·46 to 0·15)
–1·06
(–2·81 to 0·71)
–1·14
(–2·02 to –0·25)
–0·82
(–2·61 to 0·99)
Figure 4: Network meta-analysis of suicide-related outcome
Drugs are reported in order of suicide-related outcome ranking according to SUCRAs. Comparisons should be read 
from left to right. The estimate is located at the intersection of the column-defi ning treatment and the 
row-defi ning treatment. For suicidal behaviour or ideation, an OR value below 1 favours the column-defi ning 
treatment. To obtain ORs for comparisons in the opposing direction, reciprocals should be taken. Signifi cant results 
are in bold and underlined. CIT=citalopram. CLO=clomipramine. CrI=credibility interval. DUL=duloxetine. 
ESC=escitalopram. FLU=fl uoxetine. IMP=imipramine. OR=odds ratio. PBO=placebo. PAR=paroxetine. 
SER=sertraline. SUCRA=surface under the cumulative ranking curve. VEN=venlafaxine.
IMP
PBO
DUL
ESC
CLO
FLU
PAR
CIT
SER
VEN
Treatment Suicidal behaviour or ideation (OR [95% Crl])
0·42
(0·09 to 5·35)
0·40
(0·08 to 5·98)
0·34
(0·07 to 6·37)
0·32
(0·06 to 7·60)
0·35
(0·07 to 4·88)
0·96
(0·07 to 3·96)
0·26
(0·05 to 5·66)
0·73
(0·02 to 4·05)
0·16
(0·00 to 0·96)
1·14
(0·27 to 3·18)
0·61
(0·15 to 6·04)
0·91
(0·43 to 1·70)
0·94
(0·21 to 2·66)
0·57
(0·19 to 2·98)
0·60
(0·05 to 2·35)
0·14
(0·00 to 0·64)
0·61
(0·14 to 7·66)
1·09
(0·29 to 2·98)
1·09
(0·19 to 3·62)
0·57
(0·17 to 4·00)
0·69
(0·05 to 2·92)
0·16
(0·00 to 0·79)
1·37
(0·15 to 5·34)
1·02
(0·21 to 3·03)
0·44
(0·10 to 6·02)
0·87
(0·03 to 4·29)
0·19
(0·00 to 1·04)
1·08
(0·27 to 2·92)
0·69
(0·23 to 3·31)
0·69
(0·06 to 2·62)
0·15
(0·00 to 0·72)
0·69
(0·20 to 4·73)
0·85
(0·06 to 3·75)
0·19
(0·00 to 0·90)
0·93
(0·05 to 4·06)
0·21
(0·00 to 1·07)
0·51
(0·00 to 3·11)
1·07
(0·51 to 2·01)
1·08
(0·33 to 2·57)
1·41
(0·18 to 5·33)
0·90
(0·49 to 1·49)
0·89
(0·27 to 2·17)
0·89
(0·22 to 2·53)
0·57
(0·06 to 2·05)
0·13
(0·00 to 0·55)
Articles
8 www.thelancet.com   Published online June 8, 2016   http://dx.doi.org/10.1016/S0140-6736(16)30385-3
trials without industry sponsors; however, a possible 
explanation is that trials without industry sponsors tend 
to have a smaller sample size, which might result in an 
exaggerated treatment eff ect.23 By comparison with other 
antidepressants, fl uoxetine was signifi cantly more 
eff ective than nortriptyline and, in terms of 
discontinuations due to adverse events, fl uoxetine was 
better tolerated than imipramine and duloxetine. 
However, the clinical interpretation of these fi ndings is 
limited not only by the uncertainty around these 
estimates, but also by the potential bias due to selective 
reporting and the small number of trials in each node. 
We did our best to retrieve all available unpublished 
information and contacted study authors for supple-
mentary data, but we cannot rule out the possibility that 
some unpublished studies are still missing or that 
published reports might overestimate the effi  cacy of 
treatments.9,24 Moreover, poor methodology, risk of 
bias within individual studies, and potential selective 
reporting are important factors to be considered when 
interpreting the results from this meta-analysis. Without 
access to individual patient-level data, we cannot be 
confi dent about the accuracy of information contained in 
published studies or even clinical study reports.
Since 2003, many international agencies, including 
the European Medicines Agency, the US FDA, and the 
Medicines and Healthcare Products Regulatory Agency 
in the UK, have added a black box warning (the most 
serious type of warning) to the prescription drug 
labelling of antidepressants, indicating that they might 
increase the risk of suicidal thinking and behaviour in 
some children and adolescents with major depressive 
disorder.7 Our analysis found robust evidence to suggest 
a signifi cantly increased risk for suicidality (suicidal 
behaviour or ideation) for young people given 
venlafaxine. Unfortunately, due to the absence of 
reliable data on suicidality for many antidepressants, it 
was not possible to comprehensively assess the risk of 
suicidality for all drugs. However, from a clinical 
perspective, the decision maker should always consider 
the overall clinical picture, and patient management 
plans need to balance the risks and benefi ts. Children 
and adolescents taking antidepressant drugs should be 
closely monitored regardless of the treatment chosen, 
particularly at the beginning of treatment.4
This study has some limitations. First, in the GRADE 
framework, many comparisons were assessed as low or 
very low quality, which largely restricts the interpretation 
of these results. In the network, we found inconsistency 
for effi  cacy, which was mainly determined by the loop 
of fl uoxetine–nortriptyline–placebo (we did not fi nd 
heterogeneity for the tolerability outcome, probably 
because the proportion of patients who dropped out is a 
harder outcome than effi  cacy measured on a rating 
scale). We believe that this inconsistency might be a 
consequence of a cohort eff ect that relates to diff erent 
methods used in the older studies compared with those 
done more recently. Some evidence suggests that quality 
of psychopharmacological clinical trials has substantially 
changed in the past 30 years25 and other network meta-
analyses confi rmed similar fi ndings.26 Second, the 
review was restricted to trials involving children and 
adolescents with major depressive disorder. We 
excluded studies in which participants were described 
as having subsyndromal depressive symptoms, which is 
a signifi cant proportion of patients seen in real-world, 
clinical settings. Similarly, we excluded patients with 
treatment-resistant depression. We did this to reduce 
heterogeneity and inconsistency among trials in the 
network meta-analysis, but acknowledge that it restricts 
the external validity of the results. Additionally, omission 
of trials of treatment-resistant depression might have 
led to an overestimation of effi  cacy in this meta-analysis, 
because patients who are treatment resistant are clearly 
a diffi  cult-to-treat population. Third, we are aware of the 
Restoring Study 329,24 which found diff erent results to 
those of the original Study 329 when the original 
protocol was used to analyse the data. Because Restoring 
Study 329 was published after our last update of the 
search, we included the original study data, which were 
biased in favour of paroxetine over placebo. Findings 
from our review, however, were not aff ected by the 
results from this single study, because paroxetine overall 
did not show any statistical diff erence when compared 
with placebo in our analysis. The example of Restoring 
Study 329 supports the added value of network 
meta-analysis, which provides a more reliable estimate 
in terms of comparative effi  cacy.27 Finally, too few 
studies were included to be able to do a network 
meta-analysis that addressed the clinically important 
issue of antidepressant therapy for preventing relapse of 
depression in children and adolescents. Some of the 
Number 
of trials
Events/total (%)
Group 1 Group 2
Citalopram vs placebo 2 10/217 (5%) 7/205 (3%)
Duloxetine vs placebo 2 44/341 (13%) 32/225 (14%)
Escitalopram vs placebo 2 15/290 (5%) 15/294 (5%)
Fluoxetine vs placebo 7 51/521 (10%) 44/514 (9%)
Imipramine vs placebo 2 2/95 (2%) 1/87 (1%)
Mirtazapine vs placebo 2 1/170 (1%) 0/89
Nefazodone vs placebo 2 0/289 0/190
Paroxetine vs placebo 4 13/413 (3%) 7/315 (2%)
Sertraline vs placebo 2 5/189 (3%) 2/187 (1%)
Venlafaxine vs placebo 2 8/184 (4%) 0/183
Clomipramine vs 
paroxetine
1 7/58 (12%) 9/63 (14%)
Duloxetine vs fl uoxetine 2 44/341 (13%) 33/234 (14%)
Imipramine vs paroxetine 1 2/95 (2%) 5/93 (5%)
Table 2: Number of patients with suicidal behaviour or ideation 
according to study treatment
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adverse eff ects of antidepressants occur over a long 
period, meaning that positive results from short-term 
studies need to be interpreted with great caution. 
However, some long-term data suggest that fl uoxetine 
can be well tolerated and eff ective in reducing the risk 
of relapse in children and adolescents with major 
depressive disorder after 32 weeks of treatment.28 These 
data should be analysed and contextualised at the 
individual patient level (many adolescent patients with 
major depressive disorder are given drugs in adulthood 
and effi  cacy of drugs can change over time),14 but the 
data support the use of fl uoxetine as a long-term 
treatment in principle, if eff ective in the acute phase for 
children and adolescents.
The fi ndings of this comprehensive network meta-
analysis provide some evidence that fl uoxetine might 
reduce depressive symptoms in children and adolescents 
with major depressive disorder and the extent to which 
this reduction is clinically meaningful is still uncertain. 
Notwithstanding these caveats, fl uoxetine might still be 
considered the best option among antidepressants 
when a pharmacological treatment is indicated. Other 
antidepressants do not seem to be suitable as routine 
treatment options. In the clinical care of young people 
with major depressive disorder, clinical guidelines 
recommend psychotherapy (especially cognitive-behav-
ioural therapy or interpersonal therapy)4,5,29 as the fi rst-line 
intervention, and fl uoxetine should be considered only for 
patients with moderate-to-severe depression (especially 
adolescents)10 who do not have access to psychotherapy 
(eg, in low-income and middle-income countries)30 or have 
not responded to non-pharmacological interventions. 
Antidepressants are not well studied in this population, 
and further research on moderators of treatment eff ect 
and possible new interventions are needed. In all these 
cases, however, clinicians should carefully look for the 
emergence or exacerbation of suicidality and balance the 
risk–benefi t profi le of antidepressants during the acute 
treatment phase.
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